Cytokinetics, Inc. (CYTK) Posts Q1 Loss of 27c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth
May 7, 2014 9:29 AM EDTRoth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.
After markets closed Tuesday, Cytokinetics reported Q1 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.69 million.
Analyst Joseph Pnatginis noted that Cytokinetics is now prepping for the potential next steps for tirasemtiv... More
Cytokinetics (CYTK) a Buy on Partnered Pipeline, Needham & Company Says
May 7, 2014 8:41 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $15 price target on Cytokinetics (NASDAQ: CYTK) following Q1 results.
Messer comments, "Cytokinetics ended 1Q:14 with $101.9 million in cash, which we estimate is sufficient to fund the company at least through 2015. On its earnings... More
